X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs CIPLA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA CIPLA TORRENT PHARMA/
CIPLA
 
P/E (TTM) x 29.0 44.3 65.6% View Chart
P/BV x 5.5 3.9 142.9% View Chart
Dividend Yield % 1.0 0.3 296.9%  

Financials

 TORRENT PHARMA   CIPLA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
CIPLA
Mar-17
TORRENT PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,768622 284.3%   
Low Rs1,186458 258.7%   
Sales per share (Unadj.) Rs346.1181.9 190.3%  
Earnings per share (Unadj.) Rs55.212.9 428.7%  
Cash flow per share (Unadj.) Rs73.329.3 250.1%  
Dividends per share (Unadj.) Rs14.002.00 700.0%  
Dividend yield (eoy) %0.90.4 256.0%  
Book value per share (Unadj.) Rs257.1155.7 165.1%  
Shares outstanding (eoy) m169.22804.51 21.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.33.0 143.7%   
Avg P/E ratio x26.842.0 63.8%  
P/CF ratio (eoy) x20.118.4 109.3%  
Price / Book Value ratio x5.73.5 165.6%  
Dividend payout %25.415.5 163.3%   
Avg Mkt Cap Rs m249,887434,516 57.5%   
No. of employees `00011.823.0 51.1%   
Total wages/salary Rs m9,93426,338 37.7%   
Avg. sales/employee Rs Th4,971.56,349.1 78.3%   
Avg. wages/employee Rs Th843.21,143.0 73.8%   
Avg. net profit/employee Rs Th792.4449.3 176.4%   
INCOME DATA
Net Sales Rs m58,569146,302 40.0%  
Other income Rs m2,2332,287 97.6%   
Total revenues Rs m60,802148,589 40.9%   
Gross profit Rs m13,77324,758 55.6%  
Depreciation Rs m3,06913,229 23.2%   
Interest Rs m2,0561,594 129.0%   
Profit before tax Rs m10,88112,222 89.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5451,798 86.0%   
Profit after tax Rs m9,33610,354 90.2%  
Gross profit margin %23.516.9 139.0%  
Effective tax rate %14.214.7 96.5%   
Net profit margin %15.97.1 225.2%  
BALANCE SHEET DATA
Current assets Rs m53,84187,370 61.6%   
Current liabilities Rs m31,61233,081 95.6%   
Net working cap to sales %38.037.1 102.3%  
Current ratio x1.72.6 64.5%  
Inventory Days Days9787 111.7%  
Debtors Days Days8462 134.4%  
Net fixed assets Rs m42,079111,567 37.7%   
Share capital Rs m8461,609 52.6%   
"Free" reserves Rs m42,655123,645 34.5%   
Net worth Rs m43,501125,254 34.7%   
Long term debt Rs m22,40836,454 61.5%   
Total assets Rs m101,250209,532 48.3%  
Interest coverage x6.38.7 72.6%   
Debt to equity ratio x0.50.3 177.0%  
Sales to assets ratio x0.60.7 82.8%   
Return on assets %11.35.7 197.3%  
Return on equity %21.58.3 259.6%  
Return on capital %19.68.5 230.9%  
Exports to sales %034.2 0.0%   
Imports to sales %08.3 0.0%   
Exports (fob) Rs mNA50,050 0.0%   
Imports (cif) Rs mNA12,203 0.0%   
Fx inflow Rs m20,06651,066 39.3%   
Fx outflow Rs m5,30417,678 30.0%   
Net fx Rs m14,76233,388 44.2%   
CASH FLOW
From Operations Rs m10,12723,824 42.5%  
From Investments Rs m-7,869-13,127 59.9%  
From Financial Activity Rs m-1,918-13,239 14.5%  
Net Cashflow Rs m212-2,478 -8.5%  

Share Holding

Indian Promoters % 71.5 16.0 446.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 7.0 12.2 57.5%  
FIIs % 12.6 23.7 53.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 8.8 26.2 33.6%  
Shareholders   26,511 161,166 16.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - SUVEN LIFE COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS